Merck & Co., Inc. / Merck Sharp & Dohme Corp (MSD)

Industry / private company


Location: Kenilworth, NJ, United States (USA) (US) US

ISNI: 0000000122600793

ROR: https://ror.org/02891sr49

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer: a randomized phase 3 trial (2025) Cardoso F, O’Shaughnessy J, Liu Z, McArthur H, Schmid P, Cortes J, Harbeck N, et al. Journal article Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (2024) Schmid P, Cortes J, Dent R, Mcarthur H, Pusztai L, Kümmel S, Denkert C, et al. Journal article Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: Quality-of-life results from the randomized KEYNOTE-522 study (2024) Dent R, Cortés J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, et al. Journal article Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer (2024) Jahangir CA, Page DB, Broeckx G, Gonzalez CA, Burke C, Murphy C, Reis-Filho JS, et al. Journal article, Review article Association between event-free survival and overall survival in early-stage triple-negative breast cancer (2024) Huang M, Fasching P, Haiderali A, Xue W, Pan W, Karantza V, Yang F, et al. Journal article, Review article Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522 (2024) Pusztai L, Denkert C, O'Shaughnessy J, Cortes J, Dent R, McArthur H, Kümmel S, et al. Journal article Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis (2023) Cortes J, Haiderali A, Huang M, Pan W, Schmid P, Akers KG, Park JE, et al. Journal article Spatial analyses of immune cell infiltration in cancer: current methods and future directions. A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer (2023) Page DB, Broeckx G, Jahangir CA, Verbandt S, Gupta RR, Thagaard J, Khiroya R, et al. Journal article, Review article Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: a report of the international immuno-oncology biomarker working group (2023) Thagaard J, Broeckx G, Page DB, Jahangir CA, Verbandt S, Kos Z, Gupta R, et al. Journal article, Review article Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States (2023) Huang M, Fasching P, Haiderali A, Xue W, Yang C, Pan W, Zhou ZY, et al. Journal article